Novel scientific approaches and future research directions in understanding ITP

Abstract

Diagnosis of immune thrombocytopenia (ITP) and prediction of response to therapy remain significant and constant challenges in hematology. In patients who present with ITP, the platelet count is frequently used as a surrogate marker for disease severity, and so often determines the need for therapy. Although there is a clear link between thrombocytopenia and hemostasis, a direct correlation between the extent of thrombocytopenia and bleeding symptoms, especially at lower platelet counts is lacking. Thus, bleeding in ITP is heterogeneous, unpredictable, and nearly always based on a multitude of risk factors, beyond the platelet count. The development of an evidence-based, validated risk stratification model for ITP treatment is a major goal in the ITP community and this review discusses new laboratory approaches to evaluate the various pathobiologies of ITP that may inform such a model.

Keywords:

• Autoantibody
• ITP
• platelet
• receptor
• thrombocytopenia

Authorship

S.M.H and E.E.G drafted the manuscript. All authors contributed to the review of the manuscript. Images were created with the help of https://smart.servier.com/

Conflict of interest disclosure

The authors declare no competing financial interests.

Additional information

Funding

This work was supported by the National Health and Medical Research Council of Australia, the Australian Research Council, the National Blood Authority and the Australian Capital Territory Department of Health. SMH was supported by an Australian Postgraduate Scholarship.